Moreover, hypomethylating agents induced downregulation of RAD51, BRCA1, BRCA2, or HR-related genes, FEN1 or FANCD2 [118], which increased PARPi efficacy in AML, including FLT3-ITD and complex karyotype leukemic cells [119]. The gene discussed is RAD51; the disease is acute myeloid leukemia.